EIT Health is a network of best-in-class health innovators with approximately 150 partners and is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. It collaborates across borders to deliver new solutions that can enable European citizens to live longer, healthier lives.
EIT Health connects all relevant healthcare players across European borders so that innovation can happen at the intersection of research, education and business for the benefit of citizens.
It was established in 2015, as a ‘knowledge and innovation community’ (KIC) of the EIT. The EIT is made up of various KICs who each focus on a different sector, or area, of innovation – in EIT Health’s case, that is, health and aging.
EIT Health InnoStars is one of the eight geographical areas of EIT Health. It covers half of Europe, including Hungary, Italy, Poland and Portugal, as well as additional regions included in the EIT Regional Innovation Scheme – Croatia, Czechia, Estonia, Greece, Latvia, Lithuania, Slovakia, Slovenia, and Romania.
Headquartered in Budapest, EIT Health InnoStars brings together 25 Core and Associate Partners. Together with them, we are focused on promoting entrepreneurship, innovation and education in the domain of healthcare, healthy living and active ageing.
In Italy, EIT Health InnoStars is represented by 8 partners, among academic institutions, research centres and companies (University of Naples Federico II, University of Turin, Italian Institute of Technology, Synlab Italia, Synlab SDN, BioCheckUp, Bruno Kessler Foundation and ART-ER. These partners collaborate with the ARCA Consortium – as part of the RIS EIT Health Innovation Scheme – and with 3 network partners: Life Science District, Bio Industry Park Silvano Fumero and Value Services. EIT Health office is located in Naples at Center for Technologies and Life Sciences (CESTEV) of University of Naples Federico II.)
- Patchai offers intelligent digital health solutions to engage and empower patients in clinical research and care pathways. Their intelligent platform embeds an empathetic virtual companion which delivers personalised human-centric interactions to patients and collects real-world data in real-time. Read more
- Allelica focuses on reducing coronary artery disease incidence using genomic and digital technologies to personalize prevention strategies and it specialises in building fast, efficient and scalable solutions to implement clinically accessible polygenic risk scores (PRSs). Its technology combines world-class datasets with the most advanced algorithms to build PRSs with the highest predictive power for estimating disease risk. Read more
- Takis is investigating an individualised cancer vaccine for locally advanced or metastatic solid tumours (stage 3 and 4 and therefore severe with lower survival rates). They turned their attention to the pandemic in 2020, utilising the platform technology they created in cancer and directing it towards COVID-19. Read more